At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed colorectal carcinoma, pancreatic carcinoma, biliary cancer, or epithelial ovarian carcinoma
- ✓Advanced disease: metastatic or locally advanced/unresectable, not amenable to radiotherapy or locoregional therapies
- ✓Low tumor burden defined as sum of product of bidimensional measurements <70 cm2
- ✓At least one non-irradiated lesion (or irradiated with documented progression) suitable for image-guided intratumoral injection and needle biopsy
- ✕Active, severe autoimmune disease
- ✕Known active hepatitis B or C, or HIV infection
- ✕Warfarin or other anticoagulants
- ✕Treatment within 21 days with high-dose immune inhibitors, lymphotoxic monoclonal antibodies, biological therapy, cytotoxic agents, or investigational agents
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
In Brief
A Phase 2 clinical trial evaluating LOAd703 for Pancreatic Adenocarcinoma and 3 related conditions. Completed, enrolled 47 participants across 2 sites.
Detailed Summary
This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning. LOAd703 is administered by intratumoral image-guided injections. Maximum 50 patients can be enrolled. LOAd703 is an immunostimulatory gene therapy using an selection replication competent adenovirus as a gene vehicle. The virus is derived from serotype 5 adenovirus with the fiber from serotype 35. It expresses the transgenes trimerized membrane-bound isoleucine zipper (TMZ) TMZ-CD40L and 41BBL under control of a cytomegalovirus (CMV) promoter.
Study Details
Timeline
Interventions
Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL